美联储加息情况 - 2022年7月、9月和11月美联储每次会议加息75个基点，预计12月还会加息[85] 研发费用相关数据 - 2022年9月30日止三个月研发费用为238.5539万美元，较2021年增加28.0159万美元，增幅13.3%；六个月研发费用为460.7523万美元，较2021年增加71.4012万美元，增幅18.3%[89] - 2022年9月30日止三个月研发费用中股份支付费用为36.1829万美元，2021年为11.6742万美元；六个月研发费用中股份支付费用2022年为67.7923万美元，2021年为25.5027万美元[90] 研发员工人数变化 - 2022年9月30日全职研发员工人数从2021年的15人增至28人[90] 行政费用相关数据 - 2022年9月30日止三个月行政费用为106.3572万美元，较2021年减少52.546万美元，降幅33.1%；六个月行政费用为234.0678万美元，较2021年减少83.3811万美元，降幅26.3%[91] - 2022年9月30日止三个月行政费用中股份支付费用为38.0611万美元，2021年为74.5689万美元；六个月行政费用中股份支付费用2022年为80.3086万美元，2021年为126.3324万美元[92] 净亏损情况 - 2022年9月30日止六个月净亏损约690万美元，2022年和2021年3月31日止年度净亏损分别约为1860万美元和740万美元[93] 现金余额与累计亏损情况 - 2022年9月30日现金余额约1080万美元，累计亏损约4150万美元[93] 证券发行收益情况 - 2022年5月完成证券注册直接发行，净收益约740万美元[93] 经营活动使用现金情况 - 2022年和2021年9月30日止六个月经营活动使用现金分别为552.6848万美元和478.4725万美元[95]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41277 MODULAR MEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0620495 (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: March 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41277 MODULAR MEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0620495 (State or Other Jurisdiction of I ...

市场机会与需求 - 美国糖尿病市场规模为30亿美元，存在未满足的市场需求[4] - 目前美国有2700万人患有糖尿病，其中360万人需要每日胰岛素[10] - 仅有20%的胰岛素依赖型糖尿病患者使用胰岛素泵，80%依赖多次注射[12] - MODD2泵的患者年均胰岛素支出为6000美元，市场可寻址规模为226亿美元[55] - 欧洲每年在糖尿病医疗上的支出达到1560亿美元，60百万糖尿病患者[58] - 英国和德国的泵使用率较低，存在2500万到3000万美元的年度市场机会[59] 产品与技术研发 - 公司预计在2023年第二季度向FDA提交新一代胰岛素泵的申请[4] - MODD2泵的开发进度已完成75%[54] - MODD2泵将具备闭环系统和连续血糖监测功能[76] - 公司新型胰岛素泵的生产成本比领先的贴片泵低50%[28] - 公司计划通过简化产品设计来提高医生和患者的使用便利性[43] 财务展望 - 预计每位患者每年可节省1万美元的医疗费用，节省率为40%[6] - 公司预计在首次销售时即可实现盈利，毛利率为68%[40] - 公司在美国胰岛素依赖市场的用户占比为1%，预计可实现30亿美元的经常性收入[46] - 预计公司产品的定价将比Omnipod低20%，以获得优先报销[37] 竞争与市场定位 - 公司在美国市场的竞争对手包括Tandem Diabetes Care、Medtronic和Insulet[70] - 公司在FDA批准的510(k)路径上已有30年的医疗器械行业经验[62] - 公司在2022年2月14日的市场资本为3100万美元，股票价格为3.00美元[66]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2021 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-49671 MODULAR MEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0620495 (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-49671 MODULAR MEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0620495 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 16772 W. Bernardo Drive, San Diego, California 92127 (Address of pr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-49671 MODULAR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of (I.R.S. Employe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-49671 MODULAR MEDICAL, INC. (Exact name of registrant as specified in its charter) Nevada 87-0620495 (State or Other Jurisdiction of I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Registrant's Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: For the transition period from to Commission file number: 000-49671 MODULAR MEDICAL, IN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-49671 MODULAR MEDICAL, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 87-0620495 (State or Other Jurisdiction of (I.R ...